mometasone furoate (Asmanex, Nasonex)
Jump to navigation
Jump to search
Introduction
Tradename: Inhaled glucocorticoid (Asmanex).
Indications
- maintenance prophylactic treatment of asthma in patients 12 years or older
- chronic obstructive pulmonary disease
- allergic rhinitis
- atopy
- inflammatory dermatoses
Contraindications
- acute episodes of asthma, including status asthmaticus
Dosage
- start 220 ug (1 inhalation) QHS
- 440 ug (2 inhalations) BID if on oral glucocorticoid
- maximum 440 ug QD
- 880 ug QD if on oral glucocorticoid
- topical: apply 0.1% ointment/cream/lotion TID/QID.
'Twisthaler' device (dry powder inhaler) contains 30, 60 or 120 inhalations delivers 200 ug of mometasone furoate from the mouthpiece
Nasonex nasal spray 1-2 whiffs QD (generic FDA-approved March 2016)[4]
Pharmacokinetics
- maximum benefit may take 2 weeks or longer
Adverse effects
- generally mild to moderate in severity
- pharyngitis (8-13% vs 7% with placebo)
- upper respiratory tract infections (8-5% vs 7% with placebo)
- oral candidiasis (4-6% vs 2% with placebo)
- growth suppression & decreased bone mineral density has been reported
Drug interactions
- no significant drug interactions in clinical trials
- drug interaction(s) of methotrexate with biological response modifier
- drug interaction(s) of glucocorticoids with warfarin
- drug interaction(s) of NSAIDs with glucocorticoid
Mechanism of action
- inhaled glucocorticoid The average wholesale price is $155.75/120 inhalations. (2005)
More general terms
More specific terms
Component of
- mometasone/orbifloxacin/posaconazole
- mometasone/olopatadine
- florfenicol/mometasone/terbinafine
- formoterol/fumarate/mometasone
- ammonium lactate/mometasone
- ammonium lactate/lactate/mometasone
- formoterol/mometasone (Dulera)
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996.
- ↑ Prescriber's Letter 12(9): 2005 Asmanex (Mometasone Furoate Inhalation Powder) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210906&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Deprecated Reference
- ↑ 4.0 4.1 Apotex News Release. Mar 22, 2016 Apotex Launches First Generic Version of Merck's Nasonex<TM> http://www.prnewswire.com/news-releases/apotex-launches-first-generic-version-of-mercks-nasonex-573064911.html
- ↑ Department of Veterans Affairs, VA National Formulary
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=123620
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=441335
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=441336
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=55188
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4240